Loading company…
Ecublens-based Nagi Bioscience runs automated C. elegans screening for drug and chemical testing through its SydLab One platform.
Founded in 2019 in Ecublens, Switzerland, Nagi Bioscience SA provides high-content biological testing through its SydLab One automated platform, which uses C. elegans nematodes to assess drug and chemical effects. Clients include biopharma companies, academic institutions and research organizations in Europe, North America and Asia, using platform access, custom studies and contract lab services. In July 2023 the company raised CHF 12.4 million in Series A funding co-led by Swisscanto and imec.xpand. CEO Matteo Cornaglia leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in